Boston Scientific (NYSE:BSX) Stock Gets Price Target Cut from Wells Fargo & Company

Boston Scientific (NYSE:BSX) had its target price reduced by Wells Fargo & Company from $48.00 to $45.00 in a report published on Thursday morning,Benzinga reports. Wells Fargo & Company currently has an equal weight rating on the medical equipment provider’s stock.

BSX has been the subject of several other research reports. Leerink Partners dropped their price target on shares of Boston Scientific from $55.00 to $50.00 and set an “outperform” rating for the company in a research note on Thursday. Argus cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Friday, July 31st. TD Cowen restated a “buy” rating and issued a $56.00 price objective (down from $61.00) on shares of Boston Scientific in a report on Tuesday, October 20th. Royal Bank Of Canada lowered their target price on Boston Scientific from $85.00 to $70.00 and set an “outperform” rating for the company in a research report on Thursday, July 30th. Finally, Sanford C. Bernstein reaffirmed an “outperform” rating and set a $54.00 target price (down from $60.00) on shares of Boston Scientific in a report on Saturday, October 3rd. One equities research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $61.43.

Boston Scientific Stock Performance

Boston Scientific stock opened at $41.93 on Thursday. The business has a 50 day moving average of $44.78 and a 200-day moving average of $56.88. Boston Scientific has a 1 year low of $39.57 and a 1 year high of $105.65. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. The company has a market capitalization of $60.77 billion, a P/E ratio of 17.77, a P/E/G ratio of 1.03 and a beta of 0.58.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 EPS for the quarter, hitting the consensus estimate of $0.73. Boston Scientific had a net margin of 16.62% and a return on equity of 18.73%. The business had revenue of $5.14 billion for the quarter, compared to the consensus estimate of $5.09 billion. During the same period last year, the company earned $0.75 EPS. The firm’s revenue was up 1.4% compared to the same quarter last year. On average, equities research analysts predict that Boston Scientific will post 3.17 earnings per share for the current year.

Insider Buying and Selling

In other Boston Scientific news, Director David C. Habiger purchased 2,100 shares of Boston Scientific stock in a transaction that occurred on Wednesday, August 5th. The stock was acquired at an average price of $47.59 per share, with a total value of $99,939.00. Following the transaction, the director owned 17,160 shares in the company, valued at $816,644.40. This trade represents a 13.94% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Michael F. Mahoney purchased 186,240 shares of the firm’s stock in a transaction on Monday, August 3rd. The shares were acquired at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the purchase, the chief executive officer directly owned 1,590,024 shares in the company, valued at $76,845,859.92. This represents a 13.27% increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders have purchased 189,522 shares of company stock worth $9,157,810. 0.34% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in BSX. BlackRock Inc. purchased a new position in Boston Scientific during the second quarter valued at approximately $5,534,781,000. Primecap Management Co. CA bought a new stake in Boston Scientific during the 2nd quarter worth approximately $2,156,233,000. Jupiter Topco LLC bought a new stake in Boston Scientific during the 2nd quarter worth approximately $803,357,000. Janus Henderson Group PLC lifted its stake in Boston Scientific by 31.0% in the 1st quarter. Janus Henderson Group PLC now owns 16,497,366 shares of the medical equipment provider’s stock worth $1,035,202,000 after purchasing an additional 3,907,981 shares in the last quarter. Finally, Amundi lifted its stake in Boston Scientific by 1.2% in the 2nd quarter. Amundi now owns 14,296,121 shares of the medical equipment provider’s stock worth $610,158,000 after purchasing an additional 173,208 shares in the last quarter. 89.07% of the stock is owned by institutional investors.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific exceeded third-quarter earnings expectations, while management continues to support its long-term growth strategy. An eight-day cyber outage reduced quarterly sales by approximately $150 million, suggesting some of the impact may be temporary. Boston Scientific: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Some analysts still see upside: Robert W. Baird raised its price target to $51, while UBS, BTIG Research and Sanford C. Bernstein retained buy or outperform-equivalent ratings, although each lowered its target. Analysts Revise Forecasts After Q3 Results
• Neutral Sentiment: Barclays and Wells Fargo both maintain equal-weight ratings with $45 price targets, indicating limited expected upside from current levels and a wait-and-see stance.
• Negative Sentiment: Boston Scientific cut its fiscal 2026 guidance below analyst expectations, and its fourth-quarter outlook points to weaker sales. Management expects full-year organic revenue growth of about 4%, while analysts see growth challenges extending into 2027. BSX Q3 Earnings Call Flags Growth Challenges
• Negative Sentiment: The cyber incident, weakness in electrophysiology and WATCHMAN heart-device products, and pricing pressure in China are raising concerns about near-term revenue growth and execution. Boston Scientific Faces Cyber Incident and Product Pressures
• Negative Sentiment: Several firms downgraded the stock, including TD Cowen, JPMorgan, Oppenheimer and Needham. TD Cowen cut its rating to hold and reduced its target from $56 to $46, while Zacks added BSX to its Strong Sell list. New Strong Sell Stocks for October 30th
• Negative Sentiment: Relative to Intuitive Surgical, Boston Scientific is viewed as having weaker earnings momentum and less attractive near-term growth, adding competitive pressure to the investment case. Intuitive Surgical vs. Boston Scientific

About Boston Scientific

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.